EKF Diagnostics Holdings plc (AIM:EKF)

London · Delayed Price · Currency is GBP · Price in GBX

25.00

-0.50 (-1.96%)

Apr 28, 2026, 4:35 PM GMT

19.05% (1Y)

Market Cap	107.63M
Revenue (ttm)	51.56M
Net Income (ttm)	2.12M
Shares Out	430.50M
EPS (ttm)	0.00
PE Ratio	53.20
Forward PE	15.23
Dividend	n/a
Ex-Dividend Date	n/a

Volume	269,920
Average Volume	469,563
Open	25.48
Previous Close	25.50
Day's Range	24.51 - 25.90
52-Week Range	19.00 - 32.00
Beta	0.49
RSI	48.81
Earnings Date	Jun 16, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1990

Employees 297

Stock Exchange London Stock Exchange AIM

Ticker Symbol EKF

Full Company Profile

Financial Performance

In 2025, EKF Diagnostics Holdings's revenue was 51.56 million, an increase of 2.73% compared to the previous year's 50.19 million. Earnings were 2.12 million, a decrease of -66.00%.

Financial Statements

News

EKF Diagnostics Holdings Earnings Call Transcript: H2 2025

2025 was a foundational year with 3% revenue growth, improved gross margin, and strong EBITDA. Strategic execution, share buybacks, and expansion in key markets set the stage for accelerated growth, with Life Sciences and BHB segments poised for further gains.

5 weeks ago - Transcripts

EKF Diagnostics Holdings Earnings Call Transcript: H1 2025

Revenue and profit remained stable year-over-year, with gross margin improving to 50% and EBITDA up 7.4%. Strategic investments in production and Life Sciences, new contracts in growth markets, and a continued share buyback support long-term growth targets.

8 months ago - Transcripts

EKF Diagnostics Holdings Earnings Call Transcript: H2 2024

Revenue reached £50.2M with gross margin up to 48% and adjusted EBITDA at £11.3M. Strong cash generation supports a five-year plan targeting £80M+ revenue and £20M+ EBITDA by 2029, with growth focused on haemoglobin, fermentation, and BHB.

1 year ago - Transcripts